FDA gets broad discretion to approve generic drug-device combos with vague safety standards.
H.R. 5158 — Fair Price Device Act · Filed by Hillary Scholten (D-MI) · 1 cosponsor · Introduced Sep 4, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends the FDA approval process for generic drugs designed to work with medical devices. It allows generic drug makers to submit abbreviated applications (rather than full new-drug applications) when their generic drug is paired with a device, provided they can show the combination has the same clinical effect and safety as the original drug-device pairing. The bill requires applicants to submit information about device compatibility, user interface differences, and human factors studies to support equivalence.
Why we flagged it
The bill creates a streamlined regulatory pathway for generic drugs paired with devices, reducing approval friction. While framed as a cost-reduction measure, the operative mechanism delegates substantial discretion to the FDA to define equivalence standards, creating regulatory uncertainty.
What the text implies
- The bill grants the FDA broad discretion to determine what information is 'relevant' to support equivalence, potentially allowing inconsistent application across applications and creating unpredictability for manufacturers.
- The standard 'same clinical effect and safety profile' is undefined when the device component differs materially from the listed drug's device; this could permit approvals of combinations with meaningfully different delivery mechanisms if the FDA deems the difference immaterial.
The full analysis lists 4 implications of this text.
Who stands to gain
generic pharmaceutical manufacturers; medical device manufacturers seeking to pair with generics; contract research organizations conducting human factors studies